Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system

Biotechnol Prog. 2005 Jan-Feb;21(1):161-7. doi: 10.1021/bp049757a.

Abstract

Focusing on drug metabolism in liver, we constructed and evaluated a drug-metabolizing bioartificial liver (BAL) support system. In a previous study, we constructed ammonia-metabolizing CHO and hepatoma-derived HepG2 cell lines by recombination of the glutamine synthetase (GS) gene. For further mimicking of liver metabolism, the human hepatoma-derived cell line HepG2 was transformed by the pBudCE-GS-CYP3A4 vector, which contains GS and drug-metabolizing CYP 3A4 genes. The constructed GS-3A4-HepG2 cell line showed 3A4 activity higher than that of human primary hepatocytes. The drug-metabolizing activity of BAL (BAL clearance) was evaluated using this cell line. The estimated clearance was higher than that of the human hepatocyte system.

MeSH terms

  • Ammonia / metabolism
  • Animals
  • Bioreactors
  • CHO Cells
  • Cell Culture Techniques / methods
  • Cell Line, Tumor
  • Cells, Cultured
  • Cricetinae
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism*
  • Dimercaprol / metabolism*
  • Dimercaprol / pharmacokinetics
  • Glutamate-Ammonia Ligase / genetics
  • Glutamate-Ammonia Ligase / metabolism*
  • Humans
  • Liver, Artificial*
  • Metabolic Clearance Rate
  • Recombinant Proteins / metabolism
  • Transfection

Substances

  • Recombinant Proteins
  • Dimercaprol
  • Ammonia
  • Cytochrome P-450 Enzyme System
  • CYP3A protein, human
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Glutamate-Ammonia Ligase